Fate’s CAR-T prospect shows early promise in systemic sclerosis
Fate’s CAR-T prospect shows early promise in systemic sclerosis (Fierce Biotech.)
Fate Therapeutics
Fate Therapeutics is a clinical-stage biopharmaceutical company pioneering off-the-shelf NK and T-cell cancer immunotherapies derived from induced pluripotent stem cells (iPSCs). Its pipeline includes FT596 (CD19 CAR-NK), FT819 (CD19 CAR-T), and FT522 (CD19 + IL-15 CAR-NK) in hematologic malignancies and autoimmune disease.
Company Info
Sector:Biotechnology / Cell Therapy
Headquarters:San Diego, California, USA
Founded:2007
Website:www.fatetherapeutics.com/
Recent News
Leadership Team
Careers & Job Openings